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morphological analysis revealed that in most cases in all 
groups the neointima was homogenous with plaque pres-
ence only around stent struts. In the QCA and OCT analysis 
regular DES  (Prolim® and  Alex®) obtained similar results, 
whereas more pronounced response from the vessel wall was 
found in the  BiOSS® subgroup.
Keywords Stent strut thickness · Neointima 
proliferation · OCT · QCA · Stent strut cross-sectional area
Introduction
Drug eluting stents (DES) reduce the incidence of restenosis 
and thereby also the incidence of repeated revasculariza-
tions. Initially, most stents were made of stainless steel and 
therefore had relatively thick struts. Today the world applies 
the platinum-chromium or cobalt-chromium alloys as the 
stent platform, what makes possible to produce much thinner 
struts (even half smaller). The ISAR-STEREO trial demon-
strated that a thin-strut stent (≤ 100 µm) had a lower rate 
of restenosis than a thick strut stent (> 100 µm) of similar 
design [1]. Comparable results were found in several other 
trials [2–4]. The abovementioned studies suggested that 
thick struts might predispose to excessive neointima pro-
liferation, however, these results are based on studies with 
bare metal stents or the first generation DES presently not 
available on the market.
The deployment of a durable polymer DES (DP-DES) is 
a standard of care in patients with coronary artery lesions. 
However, studies assessing biodegradable polymer DES 
(BP-DES) proved the non-inferiority to DP-DES with the 
expectation for the decreased inflammatory response after 
stent implantation and, in consequence, for faster vessel 
healing [5].
Abstract The aim of this study was to compare neoin-
tima proliferation in three drug-eluting stents (DES) pro-
duced by the same company (Balton, Poland) which are 
covered with a biodegradable polymer and elute sirolimus 
(concentration: 1.0 and 1.2 µg/mm2), but have different 
stent platforms and strut thickness: stainless steel  Prolim® 
(115 µm) and BiOSS  LIM® (120 µm) and cobalt-chromium 
 Alex® (70 µm). We analyzed data of patients with quanti-
tative coronary angiography (QCA) and optical coherence 
tomography (OCT) at 12 months from BiOSS LIM Reg-
istry, Prolim Registry and Alex OCT clinical trial. There 
were 56 patients enrolled, in whom 29  Prolim® stents were 
deployed, in 11—BiOSS  LIM® and in 16—Alex stents. 
The late lumen loss was the smallest in  Prolim® subgroup 
(0.26 ± 0.17 mm) and did not differ from  Alex® subgroup 
(0.28 ± 0.47 mm). This parameter was significantly bigger in 
 BiOSS® subgroup (0.38 ± 0.19 mm; p < 0.05). In OCT anal-
ysis there was no statistically significant difference between 
 Prolim® and  Alex® subgroups in terms of mean neointima 
burden (24.6 ± 8.6 vs. 19.27 ± 8.11%) and neointima volume 
(28.16 ± 15.10 vs. 24.51 ± 17.64  mm3). In  BiOSS® group 
mean neointima burden (30.9 ± 6.2%) and mean neointima 
volume (44.9 ± 4.9 mm3) were significantly larger. The 
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The aim of this study was to compare neointima prolifera-
tion in three DES produced by the same company (Balton, 
Poland) which are covered with the same biodegradable 
polymer and elute the same drug (sirolimus concentrations: 
1.0 µg/mm2 for  Alex® and BiOSS  LIM®, while 1.2 µg/mm2 
 Prolim®) but have different stent platforms: stainless steel 
 (Prolim®, BiOSS  LIM®) or cobalt-chromium  (Alex®) and 
strut thickness: 115, 120 and 70 µm, respectively.
Materials and methods
Study population and study design
We included patients who had implanted one of the fol-
lowing stents  (Prolim®,  Alex® or BiOSS  LIM®) and had 
performed optical coherence tomography (OCT) during 
12-month angiographic follow-up. Patients participated 
in one of the following studies: Prolim Registry, BiOSS 
LIM Registry or Alex OCT study. The detailed inclusion 
and exclusion criteria are described elsewhere [6–8]. The 
appropriate Ethics Committees approved study protocols.
Study device
The BiOSS  LIM® is a coronary, dedicated bifurcation bal-
loon-expandable stent made of 316L stainless steel (strut 
thickness 120 μm; strut width 180 μm). The cover ratio 
is 18%. The stent consists of two parts, proximal and dis-
tal, joined with two connecting struts (depending on stent 
size: 1.8–2.3 mm in length) at the step-up middle zone. The 
proximal part of the stent has a larger diameter in relation 
to the distal part (diameter ratio of proximal to distal parts 
is included between 1.15 and 1.3). Maximal diameter of 
expanded stent cell is 3.5 mm [8].
The  Prolim® stent is a balloon expandable coronary stent 
with RX delivery system. The stent platform is made of a 
laser-cut 316L metallic tube with a wall thickness of 115 µm 
and strut width of 80 µm. The cover ratio is 19%. Maximal 
diameter of expanded stent cell is 1.8 mm [9].
The  Alex® stent is a balloon expandable coronary stent 
with RX delivery system. The stent platform is made of a 
laser-cut cobalt-chromium tube with a wall thickness of 
70 µm and strut width of 75 µm. The cover ratio is 18%. 
Maximal diameter of expanded stent cell is 1.5 mm [9].
All abovementioned stents are covered with a mixture of 
biodegradable poly(lactide-co-glycolide) copolymer and an 
antiproliferative substance—sirolimus. The polymer layers 
release sirolimus (1.0 µg/mm2 for Alex and BiOSS LIM and 
1.2 µg/mm2 for Prolim) in a time-controlled process due to 
their biodegradation (lasting around 8 weeks) [10].
Procedure
Percutaneous coronary interventions (PCI) were performed 
according to local standards via radial or femoral access 
using 6 Fr or 7 Fr guiding catheters. Pharmacological treat-
ment was according to the most recent guidelines [11]. 
Troponin I (TnI), creatine kinase (CK) and creatine kinase-
myocardial band (CK-MB) were measured pre-procedural, 
6 and 24 h after procedure in all patients. Periprocedural 
myocardial infarction (type 4a) was defined according to the 
third universal definition [12].
Follow-up
The assessment of the anginal status, data collection of 
adverse events, details of any subsequent coronary interven-
tions, and the use and changes in concomitant medications 
were collected at 12 ± 0.5 months. The angiographic con-
trol was planned at 12 months, in which patients in Prolim 
and BiOSS LIM Registries had OCT examination randomly 
(approximately 15% of patients), whereas in the Alex OCT 
study it was mandatory at 12 months.
Endpoints
The primary endpoint was the cumulative rate of major 
adverse cardiovascular events (MACE) consisting of car-
diac death, myocardial infarction (MI) and clinically-driven 
target lesion revascularization (TLR). Secondary endpoints 
included cardiac death, all-cause death, MI, TLR, stent 
thrombosis, late lumen loss (LLL) assessed in quantitative 
coronary angiography (QCA), the percentage of covered 
struts and neointima volume and morphology character-
istics assessed in OCT as well as the device success rate. 
Cardiac death included death resulting from an acute MI, 
sudden cardiac death, death due to heart failure and death 
due to cardiac procedures. All deaths were deemed car-
diac unless proven otherwise. MI was defined according to 
third universal definition [12]. Clinically-driven TLR was 
defined as reintervention of the target lesion due to presence 
of a symptomatic ≥ 50% diameter stenosis during follow-up. 
Device success was defined as successful deployment of the 
intended stent in the target site without a system failure. The 
definite stent thrombosis was defined as state with symptoms 
suggestive of an acute coronary syndrome and angiographic 
or pathologic confirmation of stent thrombosis. The prob-
able stent thrombosis was defined as the unexplained death 
within 30 days or target vessel myocardial infarction without 
angiographic confirmation of stent thrombosis, and the pos-
sible stent thrombosis was defined as any unexplained death 
after 30 days [13].
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Quantitative angiography analysis
All coronary angiograms were recorded after intracoronary 
administration of 200 μg of nitroglycerin. Two orthogo-
nal views were chosen to visualize the target lesion. A 
QCA analysis was performed using commercially avail-
able software (QCA-CMS version 5.0, Medis, Leiden, the 
Netherlands). Catheter calibration was used in all cases. 
The following parameters: lesion length, reference vessel 
diameter, minimal lumen diameter, % diameter stenosis, 
acute lumen gain and LLL were calculated as described 
previously [14].
Optical coherent tomography analysis
Briefly, after wiring the artery with the guidewire as 
described previously, the Dragon Fly catheter (LigthLab 
Co.) was advanced distally to the implanted stent and dur-
ing continuous contrast media flush (Iodixanol, Visipaque 
GE Healthcare), the automatic pullback was performed. 
The commercially available console (M2 or M3 by Ligth-
Lab Co.) was used. Optical coherence tomography images 
were obtained along the region of interest, which was the 
implanted stent plus 5 mm both proximal and distal. Off-
line analysis was performed after careful recalibration 
of acquired images along the reconstructed longitudi-
nal segment. Calibration was obtained by adjusting the 
z-offset, the zero-point setting of the system. The analysis 
was performed applying a dedicated off-line software (St 
Jude Medical). Quantitative measurements of the minimal 
lumen area and minimal lumen diameter were obtained in 
all consecutive frames along the region of interest using 
semi-automated algorithm. Additionally, the mean value 
of all lumen area cross-sections measured inside the region 
was calculated. Additionally, lumen volume analysis was 
performed along region of interest—all measured lumen 
area cross-sections were summed. Mean neointimal burden 
was calculated as the ratio of the mean neointima area to 
the mean stent area [7, 15].
Moreover, to assess stent apposition OCT analysis was 
performed every 0.2 mm of the stent. The stent struts 
apposition was classified as: (1) apposed (2) protruded 
and (3) malapposed according to a distance length between 
vessel wall and center of the stent strut. If such distance 
was: (1) more than 130 μm, malapposition was detected, 
(2) in range of 20 to 130 μm, protrusion was detected. The 
morphology of the neointima was analyzed according to 
the previously validated OCT criteria, and classified as 
type I (thin cap neoatheroma, lipid-rich), type II (thick-
cap, layered), type III (peri-strut, homogenous) and type 
IV (pre-existing, homogenous) [16, 17].
Statistical analysis
Continuous variables were presented as mean ± stand-
ard deviation. Categorical data were presented as num-
bers (%). Continuous variables were compared using an 
ANOVA test, and categorical data using the χ2 test. If dis-
tribution was not normal (verified with the Shapiro–Wilk 
test) for continuous variables Kruskal–Wallis test was 
used. P values of < 0.05 were considered statistically sig-
nificant. If P was < 0.05 for determining the statistical 
significance between groups appropriate post-hoc tests 
were used. Pearson correlation was applied in continuous 
variables. Additionally, univariate and multivariate linear 
regression analyses were performed. Statistical analyses 
were performed using R 3.0.2 for OS (R Foundation, 
Vienna, Austria).
Results
Baseline clinical and angiographic characteristics
A total of 56 patients were enrolled into this analysis, i.e. 
11 patients—with BiOSS  LIM® stent implanted, 29 patients 
with  Prolim®, and 16 patients—with  Alex® stent deployed. 
The baseline characteristics was comparable between 
groups, apart from the age. The mean age was significantly 
higher in the  Prolim® subgroup than in the  BiOSS® sub-
group (68 ± 10 vs. 60 ± 6 years, p < 0.05). The mean age in 
Alex group was 62 ± 9 years. The detailed clinical charac-
teristics is presented in Table 1.
In the  Prolim® and BiOSS  LIM® subgroups most patients 
presented with multivessel disease and in all groups lesions 
were of the moderate complexity. In the  Prolim® and 
 BiOSS® subgroups lesions were located most frequently 
in left anterior descending artery, 48.3 and 72.7%, respec-
tively. In the  Alex® subgroup the left circumflex artery was 
the most frequently stented vessel (43.8%). More details are 
presented in Table 2.
Procedural characteristics
The main procedural variables are presented in Table 3. The 
device success rate was 100% in all subgroups. There were 
no significant differences in procedural details as well as 
in the rate of periprocedural complications in those three 
groups.
Clinical outcomes
The clinical follow-up at 12 months was available in all 
patients. The MACE rate was: 9.1, 0 and 6.25% in the 
BiOSS  LIM®,  Prolim® and  Alex® subgroups, respectively. 
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Table 1  Baseline clinical 
characteristics
MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, UA 
unstable angina, NSTEMI non-ST-elevation myocardial infarction, STEMI ST-elevation myocardial infarc-
tion; *p < 0.05 for Prolim vs. BiOSS LIM
Baseline clinical characteristics BiOSS  LIM® Prolim® Alex® P
n = 11 (%) n = 29 (%) n = 16 (%)
Age (years) 60 ± 6 68 ± 10 62 ± 9 0.03*
Women 3 (27) 9 (31.0) 4 (25) 0.96
Hypertension 8 (72.7) 25 (86.2) 12 (75) 0.63
Hypercholesterolemia 11 (100) 24 (82.8) 9 (56.3) 0.13
Diabetes type 2 3 (27.3) 9 (31.0) 7 (43.8) 0.65
Prior MI 6 (54.5) 7 (24.1) 9 (56.3) 0.11
Prior PCI 3 (27.3) 8 (27.6) 6 (37.5) 0.79
CABG 0 2 (6.7) 0 0.9
Chronic kidney disease 0 3 (10.3) 0 0.8
Clinical indication for PCI
 Planned PCI 11 (100) 19 (65.5) 10 (62.5) 0.10
 UA 0 6 (20.7) 6 (37.5) 0.24
 NSTEMI 0 4 (13.8) 0 0.67
 STEMI 0 0 0 0.99
Table 2  Baseline angiographic 
characteristics
LAD left anterior descending artery, LM left main stem, LCx left circumflex artery, RCA right coronary 
artery, *p < 0.05 for Prolim vs. BiOSS LIM; **p < 0.05 Prolim vs. Alex; ***p < 0.05 BiOSS LIM vs. Alex
Baseline angiographic 
characteristics
BIOSS  LIM® Prolim® Alex® P
n = 11 (%) n = 29 (%) n = 16 (%)
Multivessel disease 7 (63.6) 18 (62.1) 0 0.0014**,***
Lesion type
 A 0 9 (31.0) 0 0.13
 B1 (27.3) 3 (27.3) 17 (58.6) 5 (31.3) 0.15
 B2 (54.5) 6 (54.5) 2 (6.9) 7 (43.8) 0.027*,**
 C 2 (18.2) 1 (3.5) 4 (25) 0.45
Lesion location
 LM 0 0 0 0.98
 LAD 8 (72.7) 14 (48.3) 6 (37.5) 0.31
 LCx 3 (27.3) 5 (17.2) 7 (43.8) 0.31
 RCA 0 10 (34.5) 3 (18.8) 0.23
Bifurcation lesions
 Side branch > 2 mm 10 (90.9) 4 (13.8) 7 (43.8) 0.0006*,**,***
 Side branch < 2 mm 1 (9.1) 5 (17.2) NA 0.25
 None 0 20 (68.9) 9 (56.2) 0.005*,***
Vessel tortuosity
 None—mild 7 (63.6) 17 (58.6) 9 (56.2) 0.84
 Moderate—severe 4 (36.4) 12 (41.4) 7 (43.8) 0.91
Calcification
 None—mild 8 (72.7) 20 (68.9) 13 (81.2) 0.87
 Moderate—severe 3 (27.3) 9 (31.1) 3 (18.8) 0.85
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In the observation there was one case of TLR treated with 
another DES in the  BiOSS® subgroup as well as in the  Alex® 
subgroup. There was no death or stent thrombosis.
Quantitative coronary angiography and optical 
coherence tomography analysis
The QCA data are presented in Table 4. The immediate 
angiographic success rate was 100%. Acute lumen gain 
was the lowest in the  BiOSS® subgroup (1.35 ± 0.23 mm) 
and significantly differed from acute lumen gain in the 
 Prolim® group (1.86 ± 0.39 mm) as well as in the  Alex® 
subgroup (1.78 ± 0.47 mm). Whereas the late lumen loss 
was the smallest in the  Prolim® subgroup (0.26 ± 0.17 mm) 
and it was significantly lower than in the  BiOSS® sub-
group (0.38 ± 0.19 mm). The LLL in the  Alex® subgroup 
was 0.28 ± 0.47 mm, but due to relatively high standard 
deviation (among others due to one case of TLR) it did 
not differ significantly between the other two subgroups 
(Fig. 1a). Worth mentioning is the fact that when analyzing 
the BiOSS  LIM® stent as two parts with different diameter 
(3.57 ± 0.12 × 3.0 ± 0.05 mm) we obtained the LLL in the 
proximal part of 0.36 ± 0.25 mm, and in the distal part of 
0.39 ± 0.13 mm (p = NS).
The OCT analysis data are presented in Table 5. The 
OCT at 12 months was performed in all patients. The rate 
Table 3  Procedural characteristics
*p < 0.05 for Prolim vs. BiOSS LIM
Procedural characteristics BIOSS  LIM® Prolim® Alex® P
n = 11 (%) n = 29 (%) n = 16 (%)
Device success 11 (100) 29 (100) 16 (100) 0.98
Predilatation 5 (45.5) 17 (58.6) 4 (25) 0.16
Postdilatation 2 (18.2) 8 (27.6) 4 (25) 0.90
Nominal stent diameter (mm) 3.57 ± 0.12 × 3.0 ± 0.05 3.25 ± 0.42 3.25 ± 0.35 0.7
Nominal stent length (mm) 17.45 ± 1.21 13.67 ± 2.88 16.41 ± 5.95 0.04*
Stent maximal inflation pressure (atm) 13.34 ± 1.98 15.33 ± 2.24 14.5 ± 1.8 0.56
Balloon to artery ratio 1.11 ± 0.05 1.09 ± 0.08 1.08 ± 0.09 0.87
Additional stent implantation due to dissection 0 0 0 0.98
Additional stent implantation due to lesion length 0 0 0 0.98
Table 4  Quantitative coronary angiographic analysis
RVD reference vessel diameter, %DS % diameter stenosis, MLD minimal lumen diameter, ALG acute lumen gain, LLL late lumen loss, FU 
follow-up, MV main vessel, MB main branch, *p < 0.05 for Prolim vs. BiOSS LIM; **p < 0.05 Prolim vs. Alex; ***p < 0.05 BiOSS LIM vs. Alex
Parameter BiOSS  LIM® Prolim® Alex®
n = 11 (%) n = 29 (%) n = 16 (%)
MV MB Mean
Pre stenting
 Lesion length (mm) 15.86 ± 2.65 14.47 ± 1.84 11.75 ± 3.29 0.001**,***
 RVD (mm) 3.69 ± 0.16 3.0 ± 0.13 3.35 ± 0.14 3.39 ± 0.24 2.93 ± 0.34 p < 0.01**,***
 MV—%DS 53.1 ± 9.7 44.8 ± 12.1 48.9 ± 10.9 64.6 ± 15.3 61.6 ± 11.4 0.0002**,****
 MLD (mm) 1.73 ± 0.27 1.65 ± 0.14 1.69 ± 0.2 1.21 ± 0.34 1.11 ± 0.32 0.00008*,***
Post stenting
 RVD (mm) 3.68 ± 0.19 3.02 ± 0.08 3.35 ± 0.14 3.41 ± 0.23 3.06 ± 0.4 p < 0.01**,***
 MV—%DS 9.4 ± 4.3 8.8 ± 3.4 9.1 ± 7.7 9.6 ± 4.1 5.31 ± 4.33 0.02**
 MLD (mm) 3.33 ± 0.17 2.75 ± 0.1 3.04 ± 0.14 3.08 ± 0.28 2.89 ± 0.4 0.03**
 ALG (mm) 1.6 ± 0.3 1.1 ± 0.16 1.35 ± 0.23 1.86 ± 0.39 1.78 ± 0.47 0.001*,***
Follow-up
 RVD (mm) 3.63 ± 0.25 2.96 ± 0.09 3.29 ± 0.17 3.45 ± 0.25 2.98 ± 0.45 p < 0.01**,***
 MV—%DS 18.2 ± 4.3 20.3 ± 7.4 19.3 ± 11.7 18.3 ± 6 12.69 ± 17.99 p = 0.08
 MLD (mm) 2.97 ± 0.25 2.36 ± 0.22 2.67 ± 0.23 2.82 ± 0.37 2.61 ± 0.69 p = 0.03**
 LLL (mm) 0.36 ± 0.25 0.39 ± 0.13 0.38 ± 0.19 0.26 ± 0.17 0.28 ± 0.47 p = 0.02*
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Fig. 1  QCA and OCT assessment a late lumen loss, b neointima area, c neointima volume, d neointima burden
Table 5  Optical coherence 
tomography analysis at 
12 months
*p < 0.05 for Prolim vs. BiOSS LIM; **p < 0.05 Prolim vs. Alex; ***p < 0.05 BiOSS LIM vs. Alex
Stent type BiOSS  LIM® Prolim® Alex®
Parameter n = 11 (%) n = 29 (%) n = 16 (%)
Stent apposition
 Embedded 95.8 98.6 99.2 0.00001*,***
 Protruding 2.5 1.2 0.8 0.0054*,***
 Uncovered 1.3 0.07 0.02 0.002*,***
 Malapposed 0.4 0.1 0 0.45
OCT parameters
 Mean minimal lumen area  (mm2) 3.72 ± 0.57 4.82 ± 1.41 5.22 ± 1.95 0.027***
 Mean lumen area  (mm2) 5.76 ± 0.73 6.21 ± 1.10 6.46 ± 1.8 0.35
 Mean stent area  (mm2) 8.31 ± 0.4 8.39 ± 2.26 7.94 ± 1.84 0.7
 Mean neointima area  (mm2) 2.55 ± 0.41 2.17 ± 0.37 1.49 ± 0.60 0.012*,***
 Neointima volume  (mm3) 44.9 ± 4.9 28.16 ± 15.10 24.51 ± 17.64 0.0008*,***
 Mean neointima burden (%) 30.9 ± 6.2 24.6 ± 8.6 19.27 ± 8.11 0.0009***
Neoatherosclerosis assessment
 Type I (thin cap, lipid-rich) 1 (9.1) 1 (3.4) 0 0.92
 Type II (thick cap, layered) 2 (18.2) 4 (13.8) 2 (12.5) 0.97
 Type III (peristrut, homogenous) 6 (54.5) 10 (34.5) 3 (18.8) 0.25
 Type IV (preexisting, homogenous) 2 (18.2) 14 (48.3) 11 (68.7) 0.09
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of embedded stent struts was comparable between  Prolim® 
and  Alex® subgroups (98.6 and 99.2%), and was signifi-
cantly lower in the  BiOSS® subgroup (95.8%). Similarly, 
there was no statistically significant difference between 
 Prolim® and  Alex® subgroups in terms of mean neointima 
burden (24.6 ± 8.6 vs. 19.27 ± 8.11%) and neointima volume 
(28.16 ± 15.10 vs. 24.51 ± 17.64 mm3), while in  BiOSS® 
group these parameters were significantly larger, 30.9 ± 6.2% 
and 44.9 ± 4.9  mm3 (Fig. 1b–d). Moreover, as shown on the 
Fig. 2 in each group LLL values significantly correlated 
with OCT parameters: neointima area, neointima volume 
and neointima burden.
The morphological analysis revealed that in most cases 
in all groups the neointima was homogenous with plaque 
presence only around the stent struts. Patterns did not differ 
significantly (Table 5).
In Tables 6 and 7 there are presented linear regression 
analyses for LLL value and for neointima burden value, 
respectively. Regarding LLL stent length was the only sig-
nificantly correlating value both in univariate (regression 
Fig. 2  Correlation analysis between QCA and OCT parameters for Alex, Prolim and BiOSS LIM stents
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coefficient − 0.021, 95% CI − 0.040 to − 0.002, p = 0.03) 
as well as in multivariate analysis (−  0.025, 95% CI 
− 0.046 to − 0.004, p = 0.02). Whereas when neointima 
burden was analyzed the following factors were signifi-
cant in the univariate analysis: strut width (87.676, 95% CI 
30.305–145.048, p = 0.003) and strut thickness (151.185, 
95% CI 38.862–263.508, p = 0.009) as well as in the mul-
tivariate analysis: strut width (66.406, 95% CI − 1.957 to 
134.768, p = 0.04) and postdilatation (− 4.860, 95% CI 
− 9.982 to 0.263, p = 0.04).
The new cut-off of real thin-strut stents
When analyzing the abovementioned parameters we decided 
to verify the hypothesis that not only strut thickness as 
one strut dimension is responsible for vascular response, 
but 2-dimensional parameter is more accurate (Figs. 3, 4). 
Therefore, we have introduced a new parameter (strut cross-
sectional area—StrCSA) that is the product of strut width 
and its thickness. The following values were obtained: for 
 Alex®—0.005250 mm2, for  Prolim®—0.009200 mm2, and 
for BiOSS  LIM®—0.021600 mm2.
Discussion
The LLL is a parameter widely used for assessment of 
the stent’s performance. We found that it was compara-
ble in the  Alex® and  Prolim® subgroups (0.28 ± 0.47 and 
0.26 ± 0.17 mm, respectively), whereas it was significantly 
bigger in the  BiOSS® subgroup (0.38 ± 0.19 mm, p < 0.05). 
It is worth stressing that there was no difference between 
LLL values for proximal and distal part of  BiOSS® LIM 
stent. The lack of differences between  Alex® and  Prolim® 
may be at least partly explained by higher sirolimus con-
centration on this second stent (1.2 vs. 1.0 µg/mm2). If 
we take into account the same biodegradable polymer one 
can say that sirolimus in higher concentration reduced the 
effect of thicker struts of  Prolim® stent.
The obtained results were better than those observed in 
 Cypher® stent (0.40 ± 0.65 mm, strut thickness 140 µm) 
[18], but worse than in the newest generation stents: for 
Excel  II® stent − 0.12 ± 0.34 mm (strut thickness 88 µm), 
for  Orsiro® stent—0.10 ± 0.32  mm (strut thickness 
60 µm), for  Xience® stent—0.11 ± 0.29 mm (strut thick-
ness 80 µm), and for  Supralimus® stent—0.09 ± 0.37 mm 
(strut thickness 66 µm) [19–21]. It should be emphasized 
Table 6  Late lumen loss—
linear regression
Variate Linear regression coefficient, 95% CI, p
Univariate analysis Multivariate analysis
Strut width 1.082 (− 0.706 to 2.870), p = 0.23 1.632 (− 0.488 to 3.753), p = 0.13
Strut thickness 0.443 (− 3.044 to 3.930), p = 0.80 − 1.568 (− 5.935 to 2.799), p = 0.47
Strut cross-sectional area 1.381 (0.403–5.212), p = 0.16 2.111 (1.444–2.993), p = 0.03
Stent diameter − 0.174 (− 0.432 to 0.084), p = 0.18 − 0.225 (− 0.490 to 0.039), p = 0.09
Stent length − 0.021 (− 0.040 to − 0.002), p = 0.03 − 0.025 (− 0.046 to − 0.004), p = 0.02
Predilatation 0.092 (− 0.052 to 0.237), p = 0.21 0.111 (− 0.044 to 0.265), p = 0.16
Postdilatation − 0.000 (− 0.160 to 0.159), p = 0.97 − 0.067 (− 0.226 to 0.092), p = 0.40
Diabetes 0.003 (− 0.152 to 0.158), p = 0.97 0.037 (− 0.136 to 0.209), p = 0.67
Arterial hypertension − 0.073 (− 0.256 to 0.111), p = 0.43 − 0.100 (− 0.354 to 0.153), p = 0.43
Dyslipidemia − 0.019 (− 0.198 to 0.159), p = 0.83 0.025 (− 0.254 to 0.305), p = 0.86
Table 7  Neointima burden—
linear regression
Variate Linear regression coefficient, 95% CI, p
Univariate analysis Multivariate analysis
Strut width 87.676 (30.305 to 145.048), p = 0.003 66.406 (− 1.957 to 134.768), p = 0.04
Strut thickness 151.185 (38.862 to 263.508), p = 0.009 68.154 (− 72.634 to 208.942), p = 0.34
Strut cross-sectional area 90.452 (45.211–134.749), p = 0.001 87.198 (3.334–147.348), p = 0.01
Stent diameter − 3.712 (− 12.657 to 5.233), p = 0.41 − 7.757 (− 16.276 to 0.762), p = 0.07
Stent length − 0.348 (− 1.030 to 0.334), p = 0.31 − 0.466 (− 1.135 to 0.202), p = 0.17
Predilatation 2.750 (− 2.240 to 7.741), p = 0.27 1.725 (− 3.254 to 6.704), p = 0.49
Postdilatation − 2.069 (− 7.513 to 3.376), p = 0.45 − 4.860 (− 9.982 to 0.263), p = 0.04
Diabetes − 0.669 (− 5.982 to 4.644), p = 0.80 − 0.416 (− 5.985 to 5.153), p = 0.88
Arterial hypertension − 0.553 (− 6.887 to 5.780), p = 0.86 − 4.343 (− 12.510 to 3.825), p = 0.29
Dyslipidemia 4.950 (− 1.033 to 10.934), p = 0.10 5.426 (− 3.581 to 14.432), p = 0.23
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that the highest sirolimus concentration was for  Cypher® 
comparing with  Orsiro® and  Supralimus® stents (1.4, 1.2 
and 1.2 µg/mm2, respectively).
In our study regarding LLL stent length was the only 
significantly correlating value both in univariate (regres-
sion coefficient − 0.021, 95% CI − 0.040 to − 0.002, 
p = 0.03) as well as in multivariate analysis (− 0.025, 95% 
CI − 0.046 to − 0.004, p = 0.02).
There are many factors influencing on the vessel wall 
response to stent implantation. There is not only strut thick-
ness and the drug’s type but also the type of stent platform 
and drug’s carrier, drug itself (including concentration) 
as well as accompanying diseases (such as diabetes mel-
litus). Strut width is rather forgotten and generally not ana-
lyzed parameter, because in most contemporary stents the 
cross-sectional area of the strut has the shape of the circle or 
square (width = thickness). This is a mistake in our opinion. 
After all, strut width determines the area of stent adhering 
to the wall that initiates vascular response, while strut thick-
ness is probably responsible for the duration of neointima 
proliferation. Therefore, it is rationale that for standard vas-
cular response assessment one should use the “product” of 
these two parameters (e.g. StrCSA) as better illustrating the 
geometric form of the stent strut and its potential impact on 
neointimal proliferation magnitude.
The analysis of the proposed parameter for all analyzed 
stents entitled to presume that its relatively low LLL value 
for  Prolim® stent was associated with the smaller value of 
strut width compared with BiOSS  LIM®  (Alex®—75 µm, 
 Prolim®—80  µm, BiOSS  LIM®—180  µm). StrCSA 
Fig. 3  Correlation analysis 
between late lumen loss and 
stent parameters (strut width, 
strut thickness, and strut cross-
sectional area) for Alex, Prolim 
and BiOSS LIM stents
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illustrates differences between the analyzed stents in terms 
of strut’s geometry even better  (Alex®—0.005250 mm2, 
 Prolim®—0.009200 mm2, BiOSS  LIM®—0.021600 mm2). 
Interesting conclusions could also be drawn based on the 
analysis of the StrCSA calculated for other well-known 
stents on the market. The following values were obtained: 
 Cypher®—0.019600  mm2,  Excel®—0.009520  mm2, 
 Orsiro®—0.003600 mm2,  Xience®—0.006561 mm2 and 
 Supralimus®—0.003600 mm2. This calculation definitely 
shows that the higher the StrCSA is, the bigger LLL value 
are obtained (Fig. 5).
OCT enabling single stent strut analysis seems to be 
the best method for tissue response assessment after stent 
implantation. We found almost complete vessel healing 
Fig. 4  Correlation analysis 
between neointima burden and 
stent parameters (strut width, 
strut thickness, and strut cross-
sectional area) for Alex, Prolim 
and BiOSS LIM stents
Fig. 5  Strut cross-sectional area for commonly available drug-eluting 
stents
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12 months after the index procedure for all assessed stents, 
however stent strut coverage was significantly worse for 
BiOSS  LIM® stent compared with others  (Alex® 99.2%, 
 Prolim® 98.6%, BiOSS  LIM® 95.8%,). It is very likely that 
the value of BiOSS  LIM® strut coverage rate was determined 
not only by strut thickness itself but by coronary bifurca-
tion as well. It is worth to be stressed that this parameter 
for  Alex® and  Prolim® stents was superior to everolimus-
eluting stent Xience  V® (Abbott Vascular, Santa Clara, CA) 
and zotarolimus-eluting stent Resolute  Integrity® (96.5 and 
93.5%, respectively) in the 13-month OCT substudy of the 
RESOLUTE All Comers trial [22]. On the other hand, OCT 
substudy of LEADERS trial showed that BP-DES (BioMa-
trix, strut thickness—112 µm) characterized a more com-
plete stent coverage (99.4%) as compared with DP-DES—
Cypher (97.9%) at 9 months follow-up [23]. Really, there is 
no clear and simple way to assess vessel wall response after 
stent implantation even with OCT use. There are no doubts 
that such a healing process is multifactorial.
As mentioned earlier there was no statistically significant 
difference between  Prolim® and  Alex® subgroups in terms of 
mean neointima burden (24.6 ± 8.6 vs. 19.27 ± 8.11%) and 
neointima volume (28.16 ± 15.10 vs. 24.51 ± 17.64 mm3), 
while in  BiOSS® group these parameters were significantly 
larger (30.9 ± 6.2% and 44.9 ± 4.9 mm3). This is a strong 
confirmation that the higher sirolimus concentration and 
small stent width (and StrCSA in consequence) in  Prolim® 
stent are responsible for that. Values obtained for  Prolim® 
and  Alex® subgroups were higher comparing with cobalt-
chromium Excel II stent with strut thickness of 88 µm 
(11.93 ± 6.08 mm3 and 6.77 ± 4.14%) [24]. Interestingly, 
these values were comparable to those obtained in Cypher 
stent (26.61 ± 23.06 mm3 and 15 ± 8%) [25]. We believe that 
higher sirolimus concentration on Cypher stent (1.4 μg/mm2) 
and the related drug potency explains those differences.
In our study when neointima burden was analyzed the 
following factors were significant in the univariate analysis: 
strut width (87.676, 95% CI 30.305–145.048, p = 0.003) and 
strut thickness (151.185, 95% CI 38.862–263.508, p = 0.009) 
as well as in the multivariate analysis: strut width (66.406, 
95% CI − 1.957 to 134.768, p = 0.04) and postdilatation 
(− 4.860, 95% CI − 9.982 to 0.263, p = 0.04).
Although it is often thought that OCT is the most accurate 
technique for analyzing coronary lesions, whilst QCA incurs 
systematic underestimation [26], in our study we have shown 
that in all three stents there was a strong correlation between 
LLL and OCT parameters such as neointima area, neoin-
tima volume and neointima burden (Fig. 2). Also, the role 
of StrCSA were confirmed in OCT imaging. The higher the 
“product” was, the bigger neointima burden and neointima 
volume were obtained (Fig. 4; Tables 6, 7).
We strongly believe that the proposed new parameter 
might be clinically relevant, however needs to be evaluated 
in a properly designed prospective study.
Ultimately, it is worth mentioning the OCT results 
which provided the additional insight in the characteristics 
of neointima formation. In most cases homogenous peris-
trut or preexisting atheroma was observed in all subgroups 
 (Alex®—87%,  Prolim®—83%,  BiOSS®—73%). The highest 
rate of homogenous pattern was observed in the Alex while 
the lowest in the BiOSS  LIM® stent. Probably due to the 
small number of cases these differences were not statistically 
significant, however it suggests that StrCSA value stays in 
relation with neointimal proliferation pattern. In other words 
the most favorable profile was obtained in case of  Alex® 
stent, a little bit worse in  Prolim® stent i.e. in both fulfilling 
criterion of new generation DES. We found that also for 
thick strut BiOSS  LIM® stent this rate was lower compar-
ing with Cypher stent (65%). This latter stent had a higher 
sirolimus concentration and considered as toxic mixture 
of polymers [25]. These abovementioned data are crucial 
since the homogeneous neointima pattern correlated in ear-
lier reports with a high proportion of connective tissue and 
smooth muscle cells in histopathology indicating favorable 
vessel healing, whereas, heterogenous neointima was found 
to correlate with higher presence of fibrin as compared to 
homogenous one and was associated with poorer clinical 
outcomes [27].
Study limitations
This registry has several limitations that should be acknowl-
edged. First, the sample size was relatively small and no 
sample size calculation was performed. Other limitations 
of this study are its non-randomized manner and all known 
drawbacks of registry. Also, the significance of the new 
parameter ‘strut-cross sectional area’ should be verified in 
a larger group.
Conclusions
In the QCA and OCT comparative analysis of three DES 
 (Alex®,  Prolim® and  BiOSS®) we found similar results for 
the first two, whereas a more pronounced response from 
the vessel wall was found in the  BiOSS® subgroup. Theo-
retically, the striking lack of differences between  Alex® and 
 Prolim® stents might be easily explained by a higher siroli-
mus concentration and more precise analysis of strut’s geom-
etry represented by the proposed parameter—StrCSA that 
takes into account not only strut thickness but also its width.
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